EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center
IF = 7.921 www.in-academy.uz



THE RELEVANCE OF THE USE AND RESEARCH OF DRUGS THAT HAVE A POSITIVE EFFECT ON METABOLISM

[1]Go‘zal Bobonazar qizi Nuftillaeva
[2]Sokhib Zamon o‘g‘li Rashidov
[3]Durdona Elmurod qizi Kenjaeva
[4]Kholida Dilshod qizi Normuminova
[5]Rukhshona Rustam qizi Norqulova
[1,2,3,4]Tashkent State Medical University,[5]Tashkent Pharmaceutical Research Institute

https://doi.org/10.5281/zenodo.16757600

ARTICLE INFO

Received: 01st August 2025
Accepted: 06th August 2025
Online: 07th August 2025

KEYWORDS

Absorption, distribution, metabolism, excretion, pharmaceutical research community, discovery of active metabolites.

ABSTRACT

Generally speaking, drugs that affect an organism's metabolism are those that are broken down by the body's metabolic pathways, which frequently involve liver enzymes such as those in the cytochrome P450 family. These medications' duration of action and excretion may be impacted by a variety of metabolic processes, including oxidation, reduction, hydrolysis, and conjugation. Another important factor is the gut microbiota, where bacteria either directly metabolize medications or have an impact on human metabolic processes. The majority of medications are chemically changed by different body systems to produce molecules that are easier for the body to eliminate. These chemical changes, referred to as biotransformations, mostly take place in the liver. Planning customized pharmacological interventions for patients requires an understanding of the molecular changes that medicines go through during metabolism. This exercise goes on polypharmacy, biotransformations, and drug metabolism. There is discussion of the interprofessional team's role in providing care for patients who take several drugs. The science of drug metabolism is crucial to drug research and discovery and its impacts on safety, pharmacokinetics, and pharmacodynamics should all be carefully taken into account. In order to improve PK/PD and safety profiles of drug candidates, this communication summarizes common strategies in the field of drug metabolism. These include, but are not limited to, working with medicinal chemists on structure–activity relationships (SAR) to overcome high clearance, optimizing a lead further through deuterium replacement, using prodrug approaches to get around formulation and delivery challenges, and addressing issues like species differences in metabolism, drug–drug interactions (DDI), and the formation of reactive metabolites.

Introduction: The process of finding and developing new drugs is expensive and time-consuming. According to a Tufts Center for the report of medicine Development report, developing a new medicine typically takes more than ten years and more than $2.6 billion. Therefore, implementing an ideal procedure for drug discovery and development is one of the most difficult tasks facing the pharmaceutical research community. With efficiency as one of

the main goals, rational drug design is a method to speed up this process. It combines the most recent science and technology to develop medications quickly from the lab bench to the hospital bedside. Toxins, hormones, enzymes, nutrition, drugs, and other substances all have an impact on the body's metabolic processes. These substances have the ability to alter the pace of metabolism, which affects how the body uses nutrition and energy. Absorption, distribution, metabolism, and excretion (ADME) are the processes that determine how a drug is disposed of in the body [1-4]. ADME is a crucial step in the drug design process, which investigates how a pharmacological molecule behaves after being administered. With physiological ramifications for pharmacological and toxicological effects, it is a complicated process involving transporters and metabolizing enzymes that can be crucial to drug design in order to more effectively find better therapeutic compounds. Drug metabolism in the body is a complicated biotransformation process in which distinct metabolizing enzymes structurally alter medicines to produce different compounds (metabolites). In order to minimize potential safety liabilities due to the formation of reactive or toxic metabolites, optimize lead compounds for optimal PK/PD properties, identify new chemical entities based on the discovery of active metabolites, and compare preclinical metabolism in humans and animals to ensure potential adequate coverage of human metabolites in animals and to support human dose prediction, studies on drug metabolism are essential [5-10]. In order to optimize the pharmacokinetics (PK), pharmacodynamics (PD), and safety profiles of drug candidates during drug discovery and development, this review centers on the discipline of drug metabolism. It is outside the purview of this review to discuss how protein binding and transporters affect the PK and PD characteristics of medication candidates. Numerous studies have examined abnormal energy metabolism in relation to the aforementioned disorders. Nevertheless, it is still unknown how intracellular energy conversion works, how energy metabolic pathways change dynamically, and what signals regulate which energy metabolic pathways. Notably, little is known about the diverse ways that metabolism is regulated in various tissues and organ systems, involving sex, environment, and heredity, among other things. Intercellular energy transfer interactions are the focus of recent research. For example, in pancreatic ductal adenocarcinoma, lipid-rich cancer-associated fibroblasts transport lipids to cancer cells, enhancing oxidative phosphorylation (OXPHOS) to support the proliferation of cancer cells. However, further research is needed to understand the processes of energy interactions and regulation methods since immune and non-immune cells interact in a complex way [11-15]. Consequently, a better knowledge and investigation of energy metabolism can aid in the identification and management of a number of illnesses. It is now easier to identify energy metabolism pathways because to technology improvements. However, employing imaging, mass spectrometry, and biosensors to accurately and non-invasively monitor the diverse energy metabolism across many cell types is a problem in complex physiological and pathological microenvironments. Even though multi-omics technologies are developing, a promising but little-studied avenue for research is the combination of metabolomics, spatial transcriptomics, imaging, and clustered regularly interspaced short palindromic repeats screening methods for interdisciplinary disease diagnosis. By comparing the features of cutting-edge technologies including chromatography, metabolomics, fluorescence probes, and nanobiomaterials, the authors greatly improved our

ability to research and track metabolic processes. A drawback of review articles is that they could not be as thorough and detailed in some areas as research articles that concentrate on a specific theme. In the end, this review seeks to offer a thorough comprehension of the complex patterns of energy metabolism, encourage additional research, and propel the creation of novel diagnostic and therapeutic approaches [16-20].

The main purpose of the presented manuscript is to conduct a brief analysis based on reputable scientific studies on drugs that affect metabolic processes and the relevance of their search.

Metabolic activities. Metabolic processes are divided into two categories. Anabolism and catabolism are two examples. The process by which an organism creates complex molecules from simpler ones—for instance, proteins from amino acids—is known as anabolism. Energy is stored for later use with the help of this procedure. On the other hand, catabolism releases energy for use in biological processes by disassembling complex molecules into simpler ones. The two routes work in tandem. Furthermore, depending on the availability of cells or the requirement for energy, the amphibolic pathway can be either catabolic or anabolic. In biological organisms, distinct metabolic pathways are found in various cells and organs. A connected sequence of events inside a cell is called a metabolic pathway [1,3,11,14,17]. Reactants, intermediates, and products are all considered metabolites in a metabolic pathway. These metabolites are catalyzed by enzymes, which, depending on their particular activity, produce various compounds. One enzymatic reaction's byproduct may serve as the cell's substrate for other enzymatic reactions. The electron transport chain, oxidative phosphorylation, glycolysis, and fatty acid biosynthesis are a few metabolic pathways. A metabolic pathway's function is to maintain homeostasis inside an organism. The cell's metabolites are controlled by biochemical processes based on substrate availability and energy requirements [8-13].

Different metabolic types. The pancreas secretes the hormones glucagon and insulin, which are both crucial regulators of carbohydrate metabolism. The pancreas secretes glucagon during fasting, which promotes glucose metabolism from stored glycogen, and insulin during meals containing glucose, which increases the uptake of glucose by the muscles and liver. The metabolism of glucose is based on this control. A hydroxycarboxylic acid called stored lactate is created from glucose through the processes of glycolysis, the pentose phosphate route, or alanine transamination. Cells secrete lactate due to the action of monocarboxylate transporter 4. Lactate turns into a precursor for gluconeogenesis when exercising or when starving. resistance while obese. Many essential cell components are composed of lipids, but intracellular lipid buildup and functional cell dysregulation result from the dysregulation of lipid metabolic processes [1-5]. Age, food, hormones, and inflammatory stimuli are some of the variables that affect protein metabolism. Insulin, insulin-like growth factor 1, and growth hormone are anabolic hormones, while glucagon, glucocorticoids, and catecholamines are catabolic hormones. The actions of several hormones are unknown. After being ingested and then processed by branched chain amino acid transferase, essential amino acids go through a number of changes before being redirected to the tricarboxylic acid cycle (TCA) cycle as products such as succinyl CoA. Leucine is ketogenic, valine is glucogenic, and isoleucine is both glucogenic and ketogenic. The equilibrium of

proteins in the body is determined by the processes of protein production and degradation. The term "drug biotransformation" describes the enzymatic conversion of xenobiotics to remove their pharmacological activity and render them easily excretable. This mostly entails adding functional groups or altering the drug's iso-form, which increases the parent drug molecule's hydrophilia and elimination susceptibility. Drug metabolization mostly takes place in the liver, with the colon, kidneys, and other organs (such as the heart, blood, skin, and brain) following closely after. Depending on the kind of metabolism they do, drug-metabolizing enzymes can be divided into two phases (phase 1 and phase 2) [6-12].

Energy metabolism plays a crucial role in both healthy and diseased states and is essential for maintaining physiological processes in living things. This review offers a thorough summary of developments in the field of energy metabolism research, clarifying important processes such oxidative phosphorylation, glycolysis, fatty acid metabolism, and amino acid metabolism as well as the complex regulatory mechanisms underlying them. These processes must be in homeostatic balance, but in pathological conditions like cancer, autoimmune diseases, and neurodegenerative diseases, there is a significant metabolic reprogramming that leads to mitochondrial dysfunction and impaired glucose metabolism, which hasten the course of the disease. Recent studies of important regulatory pathways, including as adenosine monophosphate-activated protein kinase, sirtuins, and the mechanistic target of rapamycin, have greatly expanded our knowledge of metabolic dysregulation and created new opportunities for innovative treatment approaches [1,7,8,11]. New technologies that promise significant gains in diagnostic accuracy include metabolomic studies, nano-biomaterials, and fluorescence probes. This review highlights the potential of metabolic research for precision diagnoses and individualized therapeutic interventions while critically analyzing recent developments and current issues. Deciphering the dynamics of intercellular energy interactions and the regulatory mechanisms of energy metabolism should be the top priorities of future research. The creation of multi-target medications that work in tandem with current treatments like immunotherapy and dietary changes, while incorporating state-of-the-art gene-editing technology and multi-omics methodologies, may improve therapeutic efficacy. In order to create individualized treatment plans and, eventually, give patients more precise medical care, personalized metabolic analysis is essential. The goal of this review is to advance knowledge and enhance the use of energy metabolism to support creative approaches to diagnosis and treatment [9-14].

Physiology of metabolic pathway disruption and inter-organ connectivity. Depending on the type of metabolism being investigated, it is essential to comprehend the physiology of organ interconnections because metabolism entails the harmonious signaling of several organs. Several organs and specialized tissues are involved in human metabolism, which breaks down, stores, and releases energy from food. The liver is one of the main organs involved in metabolism. Hepatocytes are primarily responsible for carrying out the wide variety of distinct biotransformation activities. Hepatocytes, cholangiocytes, and other liver parenchymal cells are encircled by a network of non-parenchymal cells in the hepatic sinusoid, such as sinusoidal endothelial cells, hepatic stellate cells, and liver macrophages (Kupffer cells), which support and control immunological responses and metabolic processes [11-15]. Hepatocytes are subjected to different biophysical and biochemical cues depending

on where they are located in the periportal, mid-, and pericentral zones of the hepatic lobules. Adipose tissue and the liver are specialized organs for energy storage. Adipose tissue, which accounts for 20–50% of body weight, is a potent endocrine organ and a storage organ for fatty acids. There is proof that visceral fat affects metabolism via secreting FFAs and adipokines. The most prevalent type of muscle in the human body is skeletal muscle tissue, which makes up 70–80% of cell mass but only 40–45% of total body weight. Muscle tissue not only supplies the mechanical forces needed for movement, but it also stores energy. One important process at the heart of both innate and adaptive immune control is immuno-metabolism. Inflammatory cytokines released in obese adipose tissue were found to be the cause of metabolic disease in early research because they aggravate the inflammatory loop by triggering a communication between immune cells and metabolism. Different immune cell subsets are produced by metabolic pathways that are closely related to cell signaling and differentiation. These subsets respond differently to biochemical and biophysical stimuli in their microenvironments, resulting in distinct metabolic fates [17-21].

Metabolic illnesses. A worldwide epidemic, obesity impacts adults, children, and newborns. Over the last three decades, the prevalence of obesity has almost doubled worldwide, and in the US, it is at its highest level ever. For the first time in history, there are more obese and overweight people than underweight people in the world. Both industrialized and developing nations have seen a sharp rise in the prevalence of abdominal obesity. The prevalence of childhood and teenage obesity has also risen. Over 60% of children who are obese will grow up to be obese adults, and over one-third of youngsters in the US are overweight or obese. Additionally, there is an obesity epidemic among infants six months of age and younger, a demographic for which poor dietary choices and insufficient exercise cannot account for the problem [3-8]. In addition to humans, other animals that have been shown to be affected by the obesity epidemic include domestic dogs and cats, horses, feral rats, and primates and rodents housed in research colonies. Treating the co-morbidities that usually accompany obesity, such as cardiovascular disease, hypertension, dyslipidemia, liver and gallbladder disease, insulin resistance, hyperglycemia, and type 2 diabetes, is linked to staggering health care expenditures. Obstructive sleep apnea, cancer, and neurological illnesses are also linked to obesity. Therefore, identifying the causes of obesity has emerged as a significant public health concern [9-13].

Factors That May Impact Metabolism. A disruption in metabolic processes may have a negative impact on an individual's health. Diabetes is a well-known condition in which either too much or too little insulin is produced, resulting in uncontrolled blood glucose levels. The overproduction of thyroid hormones, or hyperthyroidism, can raise metabolism and result in alterations to menstrual cycles, heartbeats, weight loss, and perspiration. Infertility, joint pain, and abrupt weight gain are all consequences of hypothyroidism, which also interferes with metabolism. Women are more likely to have hyperthyroidism and hypothyroidism. Metabolism-related conditions can vary in severity and impact quality of life; they all require medical attention. Some disorders are inherited, while others are tied to lifestyle choices [15-21].

Discussion. Three types of life-sustaining processes make up metabolism. The first relates to the biochemical processes that occur in various tissues and produce or use energy

in order to preserve homeostasis. The second is the synthesis of building blocks from food, like lipids and proteins, to support bodily processes. The removal of xenobiotics and metabolic waste is the last component of metabolism. The stomach, liver, adipose tissue, pancreas, kidney, and muscles are the main organs involved in metabolism. Through various signaling pathways triggered by hormones and morphogens, these organs cooperate during metabolic control to give the body the right amount of energy. Through a variety of pathways, immune-related activities also impact metabolic function. Numerous studies mentioned above emphasize how crucial development is as a sensitive period for programming every facet of metabolism [1-5]. Together with the significance of diet during development and throughout life on metabolism, the ability of environmental chemicals with endocrine activity to change metabolism programming, and the role of exercise in regulating weight and glucose metabolism, these factors combine to create the ideal environment for metabolic disease. The sensitivity or set point for obesity, diabetes, and liver disease is created during the crucial prenatal and early life years. Here, we have demonstrated that MDCs that disrupt the normal developmental trajectories of adipose tissue, the pancreas, muscle, liver, GI tract, and the brain can change sensitivity or set points for the development of various disorders. For biological systems to maintain the equilibrium between energy supply and demand, energy metabolism must be precisely regulated. With an emphasis on important mechanisms like glycolysis, OXPHOS, FAO, and amino acid metabolism, this overview describes the well-established functions of energy metabolism in both health and sickness [6-11]. Energy metabolism disturbances cause abnormalities in the differentiation of immune cell types, such as Th17 cells, Tfh cells, Treg cells, and macrophages, in addition to the aberrant proliferation of cancer cells and synovial fibroblasts. The expression of several proteins and enzymes involved in energy metabolism is also significantly altered by these disturbances. Metabolism is regulated by complex signalling pathways that centrally involve hormones such as insulin and glucagon secreted by the pancreas, provoking effects in energy-consuming organs including the muscle, liver and adipose tissue. The secretion of these signalling molecules differs with glucose availability, which regulates the adaptive metabolic response. Dysfunction of metabolism has been linked to the onset of a variety of diseases caused by disturbance of homeostatic mechanisms required to maintain proper cell function. A complicated web of biochemical processes, metabolism can be influenced by dietary choices, lifestyle decisions, genetic disorders, and medical conditions. In order to improve general nutrition and health as well as develop cures and treatments for a wide range of medical diseases, it is essential to comprehend the biochemistry of metabolism [20-24].

Conclusions. Diet, lifestyle, genetics, and health problems can all have an impact on metabolism, which is a complicated web of biochemical activities. Designing therapies and treatments for a wide range of medical illnesses as well as enhancing general nutrition and health require an understanding of the biochemistry of metabolism.Over the past ten years, OoC technology has developed quickly thanks to advancements in stem cell technologies, biomarkers, three-dimensional cell culture techniques, and microfabrication techniques.

Existing OoC platforms will be enhanced by new methods and materials, though, like the use of innovative biomaterials (taking into account the significance of cell–material communication), the integration of high-throughput microfluidic systems (enabling parallel

experimentation), and the integration of innovative sensor arrays. Therefore, we are optimistic that the notable developments in MOC technology will promote and expand its application in biological and clinical research, as well as assist in transforming non-clinical research into precision medicine with enhanced capacities for drug discovery and personalized disease modeling.

The pancreatic hormones insulin and glucagon, which have an impact on energy-consuming organs like muscle, liver, and adipose tissue, are at the center of the intricate signaling pathways that control metabolism. These signaling molecules' release varies according to the availability of glucose, which controls the adaptive metabolic response. Numerous disorders have been associated with metabolic dysfunction, which is a disruption of the homeostatic processes necessary to preserve healthy cell function.

In summary, despite obstacles and optimism, energy metabolism modulation as a therapeutic approach exhibits significant promise. Thorough and thorough efforts in both fundamental and translational research will be required to successfully incorporate these discoveries into clinical practice.

References:

1. Susa ST, Hussain A, Preuss CV. Drug Metabolism. [Updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK442023/
2. Zhang Z, Tang W. Drug metabolism in drug discovery and development. Acta Pharm Sin B. 2018 Sep;8(5):721-732. doi: 10.1016/j.apsb.2018.04.003.
3. Open Resources for Nursing (Open RN); Ernstmeyer K, Christman E, editors. Nursing Pharmacology [Internet]. 2nd edition. Eau Claire (WI): Chippewa Valley Technical College; 2023. Chapter 1 Pharmacokinetics & Pharmacodynamics. Available from: https://www.ncbi.nlm.nih.gov/books/NBK595006/
4. Liu, H., Wang, S., Wang, J. et al. Energy metabolism in health and diseases. Sig Transduct Target Ther 10, 69 (2025). https://doi.org/10.1038/s41392-025-02141-x
5. Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, Huai C, Shen L, Zhang N, He L, et al. Cytochrome P450 Enzymes and Drug Metabolism in Humans. International Journal of Molecular Sciences. 2021; 22(23):12808. https://doi.org/10.3390/ijms222312808
6. Patel, R.; Barker, J.; ElShaer, A. Pharmaceutical excipients and drug metabolism: A mini-review. Int. J. Mol. Sci. 2020, 21, 8224.
7. Tao, G.; Huang, J.; Moorthy, B.; Wang, C.; Hu, M.; Gao, S.; Ghose, R. Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity. Expert Opin. Drug Metab. Toxicol. 2020, 16, 1109–1124.
8. Coelho, M.M.; Fernandes, C.; Remião, F.; Tiritan, M.E. Enantioselectivity in drug pharmacokinetics and toxicity: Pharmacological relevance and analytical methods. Molecules 2021, 26, 3113.
9. Rendic, S.P. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects. Arch. Toxicol. 2021, 95, 1535–1546.

10. Krkoška, M.; Svobodová, J.; Kabátková, M.; Zapletal, O.; Hyršlová Vaculová, A.; Nekvindová, J.; Vondráček, J. Deregulation of signaling pathways controlling cell survival and proliferation in cancer cells alters induction of cytochrome P450 family 1 enzymes. Toxicology 2021, 461, 152897.
11. Wang, Y.; He, X.; Li, C.; Ma, Y.; Xue, W.; Hu, B.; Wang, J.; Zhang, T.; Zhang, F. Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification. Eur. J. Med. Chem. 2020, 193, 112235.
12. Brown, S.A.; Pereira, N. Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine. J. Pers. Med. 2018, 8, 8.
13. Navarro-Mabarak, C.; Camacho-Carranza, R.; Espinosa-Aguirre, J.J. Cytochrome P450 in the central nervous system as a therapeutic target in neurodegenerative diseases. Drug Metab. Rev. 2018, 50, 95–108.
14. Sneha, S.; Baker, S.C.; Green, A.; Storr, S.; Aiyappa, R.; Martin, S.; Pors, K. Intratumoural cytochrome P450 expression in breast cancer: Impact on standard of care treatment and new efforts to develop tumour-selective therapies. Biomedicines 2021, 9, 290.
15. Fritsche K, Ziková-Kloas A, Marx-Stoelting P, Braeuning A. Metabolism-Disrupting Chemicals Affecting the Liver: Screening, Testing, and Molecular Pathway Identification. International Journal of Molecular Sciences. 2023; 24(3):2686. https://doi.org/10.3390/ijms24032686
16. Heindel, J.J.; Blumberg, B.; Cave, M.; Machtinger, R.; Mantovani, A.; Mendez, M.A.; Nadal, A.; Palanza, P.; Panzica, G.; Sargis, R.; et al. Metabolism disrupting chemicals and metabolic disorders. Reprod. Toxicol. 2017, 68, 3–33.
17. Alves-Bezerra, M.; Cohen, D.E. Triglyceride Metabolism in the Liver. Compr. Physiol. 2017, 8, 1–22.
18. Hamoud, A.R.; Weaver, L.; Stec, D.E.; Hinds, T.D., Jr. Bilirubin in the Liver-Gut Signaling Axis. Trends Endocrinol. Metab. 2018, 29, 140–150.
19. Javed, K.; Fairweather, S.J. Amino acid transporters in the regulation of insulin secretion and signalling. Biochem. Soc. Trans. 2019, 47, 571–590.
20. Kersten, S.; Stienstra, R. The role and regulation of the peroxisome proliferator activated receptor alpha in human liver. Biochimie 2017, 136, 75–84.
21. Wolf Greenstein, A.; Majumdar, N.; Yang, P.; Subbaiah, P.V.; Kineman, R.D.; Cordoba-Chacon, J. Hepatocyte-specific, PPARgamma-regulated mechanisms to promote steatosis in adult mice. J. Endocrinol. 2017, 232, 107–121.
22. Mutemberezi, V.; Guillemot-Legris, O.; Muccioli, G.G. Oxysterols: From cholesterol metabolites to key mediators. Prog. Lipid Res. 2016, 64, 152–169.
23. Tanianskii, D.A.; Jarzebska, N.; Birkenfeld, A.L.; O'Sullivan, J.F.; Rodionov, R.N. Beta-Aminoisobutyric Acid as a Novel Regulator of Carbohydrate and Lipid Metabolism. Nutrients 2019, 11, 524.
24. Caudle, K.E.; Sangkuhl, K.; Whirl-Carrillo, M.; Swen, J.J.; Haidar, C.E.; Klein, T.E.; Gammal, R.S.; Relling, M.V.; Scott, S.A.; Hertz, D.L.; et al. Standardizing CYP2D6 genotype to phenotype translation: Consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics working group. Clin. Transl. Sci. 2020, 13, 116–124.